Ignite Creation Date:
2024-07-17 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06465329
Status:
RECRUITING
Last Update Posted:
2024-06-18
First Post:
2024-06-13
Brief Title:
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer NSCLC
Sponsor:
Regeneron Pharmaceuticals
Organization:
Regeneron Pharmaceuticals
Organization Data
Organization:
Regeneron Pharmaceuticals
Class:
INDUSTRY
Study ID:
R2810-ONC-2268
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Regeneron Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None